Evidence map›Paper›PMID 28400594›Full record

ReviewEmerging microbes & infections2017

Histo-blood group antigens as receptors for rotavirus, new understanding on rotavirus epidemiology and vaccine strategy.

Xi Jiang, Yang Liu, Ming Tan

Abstract readReview
In one paragraph

Review in Emerging microbes & infections, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Species-SpecificMarine drugs · 2023
    Article
  13. Article
  14. Article
  15. Genome Analysis of the G6P6 Genotype of Porcine Group C Rotavirus in China.Animals : an open access journal from MDPI · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Frontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xi JiangCincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
Yang LiuCincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.
Ming TanCincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.

Funding

Novel vaccine against NorovirusR01AI089634 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI JIANG, XI · 2010 to 2014
$4.7M
Norovirus P Particle, A Multifunctional Platform For Vaccine DevelopmentR21AI092434 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI TAN, MING · 2011 to 2012
$421k
Prevalence of P[6] and P[11] rotaviruses in developing countriesR21AI130631 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI JIANG, XI · 2017 to 2018
$402k
NIAID NIH HHS R01 AI089634NIAID NIH HHS R21 AI092434NIAID NIH HHS R21 AI130631
6 · The paper itself

Abstract

The success of the two rotavirus (RV) vaccines (Rotarix and RotaTeq) in many countries endorses a live attenuated vaccine approach against RVs. However, the lower efficacies of both vaccines in many low- and middle-income countries indicate a need to improve the current RV vaccines. The recent discovery that RVs recognize histo-blood group antigens (HBGAs) as potential receptors has significantly advanced our understanding of RV diversity, evolution and epidemiology, providing important new insights into the performances of current RV vaccines in different populations and emphasizing a P-type-based vaccine approach. New understanding of RV diversity and evolution also raises a fundamental question about the 'Jennerian' approach, which needs to be addressed for future development of live attenuated RV vaccines. Alternative approaches to develop safer and more cost-effective subunit vaccines against RVs are also discussed.

Indexed as

Virus AttachmentBlood Group AntigensDrug DiscoveryHumansReceptors, VirusRotavirusRotavirus InfectionsRotavirus VaccinesBlood Group AntigensReceptors, VirusRotavirus Vaccines

Identifiers

PMID28400594
PMCPMC5457676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.